Suppr超能文献

用于青光眼研究的多重蛋白质分析。

Multiplex protein analysis for the study of glaucoma.

机构信息

Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University, Edward S. Harkness Eye Institute, New York, NY, USA.

出版信息

Expert Rev Proteomics. 2021 Oct;18(10):911-924. doi: 10.1080/14789450.2021.1996232. Epub 2021 Oct 29.

Abstract

INTRODUCTION

Glaucoma, a leading cause of irreversible blindness in the world, is a chronic neurodegenerative disease of multifactorial origin. Extensive research is ongoing to better understand, prevent, and treat progressive degeneration of retinal ganglion cells in glaucoma. While experimental models of glaucoma and postmortem tissues of human donors are analyzed for pathophysiological comprehension and improved treatment of this blinding disease, clinical samples of intraocular biofluids and blood collected from glaucoma patients are analyzed to identify predictive, diagnostic, and prognostic biomarkers. Multiplexing techniques for protein analysis offer a valuable approach for translational glaucoma research.

AREAS COVERED

This review provides an overview of the increasing applications of multiplex protein analysis for glaucoma research and also highlights current research challenges in the field and expected solutions from emerging technological advances.

EXPERT OPINION

Analytical techniques for multiplex analysis of proteins can help uncover neurodegenerative processes for enhanced treatment of glaucoma and can help identify molecular biomarkers for improved clinical testing and monitoring of this complex disease. This evolving field and continuously growing availability of new technologies are expected to broaden the comprehension of this complex neurodegenerative disease and speed up the progress toward new therapeutics and personalized patient care to prevent blindness from glaucoma.

摘要

简介

青光眼是全球主要的不可逆盲眼病,是一种多因素起源的慢性神经退行性疾病。为了更好地理解、预防和治疗青光眼中原发性节细胞的进行性变性,正在进行广泛的研究。虽然正在对青光眼的实验模型和人类供体的组织进行分析,以了解其病理生理学并改善对这种致盲疾病的治疗,但也在分析来自青光眼患者的眼内生物流体和血液的临床样本,以识别预测、诊断和预后的生物标志物。用于蛋白质分析的多重分析技术为转化性青光眼研究提供了一种有价值的方法。

涵盖的领域

这篇综述提供了对青光眼研究中越来越多的多重蛋白分析应用的概述,还强调了该领域当前的研究挑战和新兴技术进步预期的解决方案。

专家意见

用于蛋白质多重分析的分析技术可以帮助揭示神经退行性过程,从而增强对青光眼的治疗效果,还可以帮助确定分子生物标志物,以改善对这种复杂疾病的临床检测和监测。这个不断发展的领域和新技术的不断涌现,预计将拓宽对这种复杂神经退行性疾病的理解,并加速新疗法的进展和个性化患者护理,以防止青光眼致盲。

相似文献

1
Multiplex protein analysis for the study of glaucoma.
Expert Rev Proteomics. 2021 Oct;18(10):911-924. doi: 10.1080/14789450.2021.1996232. Epub 2021 Oct 29.
2
[Aiming for zero blindness].
Nippon Ganka Gakkai Zasshi. 2015 Mar;119(3):168-93; discussion 194.
3
Neuroprotection in glaucoma: Mechanisms beyond intraocular pressure lowering.
Mol Aspects Med. 2023 Aug;92:101193. doi: 10.1016/j.mam.2023.101193. Epub 2023 Jun 16.
4
Exploring Epigenetic Modifications as Potential Biomarkers and Therapeutic Targets in Glaucoma.
Int J Mol Sci. 2024 Feb 29;25(5):2822. doi: 10.3390/ijms25052822.
5
A proteomics view of the molecular mechanisms and biomarkers of glaucomatous neurodegeneration.
Prog Retin Eye Res. 2013 Jul;35:18-43. doi: 10.1016/j.preteyeres.2013.01.004. Epub 2013 Feb 5.
6
A decade of proteomics studies of glaucomatous neurodegeneration.
Proteomics Clin Appl. 2014 Apr;8(3-4):154-67. doi: 10.1002/prca.201300115. Epub 2014 Feb 16.
7
Early localized alterations of the retinal inner plexiform layer in association with visual field worsening in glaucoma patients.
PLoS One. 2021 Feb 25;16(2):e0247401. doi: 10.1371/journal.pone.0247401. eCollection 2021.
8
Neuroprotection in Glaucoma: Animal Models and Clinical Trials.
Annu Rev Vis Sci. 2017 Sep 15;3:91-120. doi: 10.1146/annurev-vision-102016-061422. Epub 2017 Jul 21.
9
Candidate Glaucoma Biomarkers: From Proteins to Metabolites, and the Pitfalls to Clinical Applications.
Biology (Basel). 2021 Aug 10;10(8):763. doi: 10.3390/biology10080763.
10
Intracameral injection of a chemically cross-linked hydrogel to study chronic neurodegeneration in glaucoma.
Acta Biomater. 2019 Aug;94:219-231. doi: 10.1016/j.actbio.2019.06.005. Epub 2019 Jun 6.

本文引用的文献

1
Molecular regulation of neuroinflammation in glaucoma: Current knowledge and the ongoing search for new treatment targets.
Prog Retin Eye Res. 2022 Mar;87:100998. doi: 10.1016/j.preteyeres.2021.100998. Epub 2021 Aug 1.
3
TGFβ1, MMPs and cytokines profiles in ocular surface: Possible tear biomarkers for pseudoexfoliation.
PLoS One. 2021 Apr 29;16(4):e0249759. doi: 10.1371/journal.pone.0249759. eCollection 2021.
5
Advances in quantitative high-throughput phosphoproteomics with sample multiplexing.
Proteomics. 2021 May;21(9):e2000140. doi: 10.1002/pmic.202000140. Epub 2021 Mar 30.
6
Regulation of distinct caspase-8 functions in retinal ganglion cells and astroglia in experimental glaucoma.
Neurobiol Dis. 2021 Mar;150:105258. doi: 10.1016/j.nbd.2021.105258. Epub 2021 Jan 9.
8
High-Resolution Transcriptomic and Proteomic Profiling of Heterogeneity of Brain-Derived Microglia in Multiple Sclerosis.
Front Mol Neurosci. 2020 Oct 22;13:583811. doi: 10.3389/fnmol.2020.583811. eCollection 2020.
9
Inflammation in Glaucoma: From the back to the front of the eye, and beyond.
Prog Retin Eye Res. 2021 Jul;83:100916. doi: 10.1016/j.preteyeres.2020.100916. Epub 2020 Oct 17.
10
The use and limitations of single-cell mass cytometry for studying human microglia function.
Brain Pathol. 2020 Nov;30(6):1178-1191. doi: 10.1111/bpa.12909. Epub 2020 Nov 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验